BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 18, 2011
View Archived Issues
Archaeosome-encapsulated RD T-cell antigen vaccine efficacious against experimental tuberculosis
Read More
Herceptin conjugates induce programmed necrotic tumor cell death
Read More
Diamyd to concentrate resources on pain portfolio
Read More
Eisai enrolls participants in phase III rufinamide study
Read More
Cytos Biotechnology to focus on lead product
Read More
Verona Pharma reports data from phase II RPL-554 trial
Read More
Emergent BioSolutions begins trial of TRU-016 in relapsed, indolent lymphoma
Read More
Allos Therapeutics begins phase III registration trial of Folotyn
Read More
First Ultragenyx product enters clinical development
Read More
New GPR52 receptor agonists prepared by Takeda
Read More
Researchers at Pfizer disclose new gamma-secretase modulators
Read More
Lexicon Pharmaceuticals reports phase II data on telotristat etiprate
Read More
Nippon Chemiphar presents new GPR119 receptor agonists
Read More
Scientists at Vertex design novel PKC-theta inhibitors
Read More
Sanofi synthesizes novel fatty-acid amide hydrolase 1 inhibitors
Read More
New prodrugs of proteasome inhibitors designed by Cephalon
Read More
Roche obtains FDA approval for melanoma drug and companion diagnostic
Read More
FDA approves Intersect ENT's Propel implant
Read More
Gentium withdraws defibrotide NDA
Read More
Dual FGF/VEGF pathway inhibitor shows promise in limiting tumor resistance to VEGF inhibition
Read More
FDA accepts for review Protalix Biotherapeutics' resubmitted NDA for taliglucerase alfa
Read More
New approval for Progensa PCA3 test
Read More
Zogenix's phase III trial of Zohydro meets primary endpoint
Read More
Paladin Labs to acquire Labopharm
Read More
